In a strategic move to align with Nasdaq’s regulatory requirements, bioAffinity Technologies Inc., a pioneering biotechnology firm based in San Antonio, United States, has announced a significant corporate action. On August 20, 2026, the company filed a current report detailing a reverse stock split of its common shares. This decision, approved by the board, involves a 1-for-15 reverse split, set to take effect at 4:01 p.m. Eastern time on August 21, with the changes reflected in the Nasdaq market at the opening of trading on August 24.
The primary objective of this reverse stock split is to ensure compliance with Nasdaq’s minimum bid-price requirement. As of August 20, 2026, the company’s close price stood at $0.40, a significant drop from its 52-week high of $13.50 on September 14, 2025. This decline in stock price necessitated the reverse split to maintain its listing on the Nasdaq, a critical platform for the company’s visibility and investor engagement.
In addition to the reverse split, shareholders will receive a cash payment in lieu of any fractional shares resulting from the reclassification. This measure ensures that shareholders are compensated fairly, maintaining their investment value despite the structural changes in share distribution.
The filing accompanying the reverse stock split included a certificate of amendment to the company’s certificate of incorporation, a press release, and the usual regulatory disclosures. Importantly, the company reported no material changes to its business or financial condition, underscoring its continued focus on its core mission.
bioAffinity Technologies Inc. has been at the forefront of the Health Care sector, specializing in the development of proprietary noninvasive diagnostic tests and cancer therapeutics. These innovations are designed to target cancer cells and cell populations indicative of diseased states, leveraging advanced technology to serve customers across the United States. The company’s commitment to revolutionizing the diagnostic and therapeutic landscape for various diseases, particularly cancer, remains unwavering.
Since its Initial Public Offering (IPO) on June 2, 2022, bioAffinity Technologies has navigated the complexities of the biotechnology industry with a clear vision. Despite the challenges reflected in its current market cap of $3,310,000 and a negative price-to-earnings ratio of -0.059, the company continues to pursue its strategic objectives with determination.
For those interested in learning more about bioAffinity Technologies’ innovative work and offerings, further information is available on their website at www.bioaffinitytech.com . As the company moves forward, it remains dedicated to its mission of transforming healthcare through cutting-edge biotechnological advancements.
